San Francisco-based DiCE Molecules has appointed Dr Richard Scheller to its board of directors.
Dr Scheller brings nearly 20 years of leadership in drug discovery research and development to DiCE Molecules, and currently serves as chief scientific officer and head of therapeutics at 23andMe.
Prior to this, Dr Scheller spent 14 years at Roche’s Genentech, the US biotechnology corporation, where he held a number of R&D roles including executive vice president of research and early development.
Between 1982 and 2001, Dr Scheller was a professor in Stanford University’s department of biological sciences, and the department of molecular and cellular physiology.
Since 2004, he has served as an adjunct professor in the department of biochemistry and biophysics at the University of California, San Francisco.
Kevin Judice, president and chief executive of DiCE, said: “I have known Richard for years and had the opportunity to work with him early in my career at Genentech – he is truly a visionary and a distinguished leader in oncology, neuroscience, immunology and infectious disease drug development.
“I am delighted to have the opportunity to work with him again as a member of our board and we look forward to his guidance and leadership as we further prove out our science and bring potential drug targets into the clinic.”